CAMBRIDGE, Massachusetts, July 23, 2026
Nona Biosciences has announced a strategic research collaboration with the Medical University of Vienna (MedUni Vienna) to accelerate the discovery and development of fully human antibodies targeting infectious diseases. Through the collaboration, the inter-university Ignaz Semmelweis Institute, led by Prof. Florian Krammer, will leverage Nona’s proprietary H2L2 Harbour Mice® platform to generate fully human antibodies that support research, diagnostic, and therapeutic development programs. The partnership combines Nona’s advanced antibody discovery technology with MedUni Vienna’s internationally recognized expertise in infectious disease research, with the shared goal of advancing next-generation antiviral therapies and strengthening global pandemic preparedness. The agreement reinforces the growing importance of innovative antibody technologies in accelerating biomedical research and expanding future treatment options for emerging infectious diseases.
H2L2 Harbour Mice® Platform Powers Fully Human Antibody Discovery
At the center of the collaboration is Nona Biosciences’ H2L2 Harbour Mice® platform, an advanced transgenic mouse technology designed to generate fully human monoclonal antibodies following immunization. Unlike conventional antibody discovery systems, the platform produces antibodies with fully human structures, enabling researchers to rapidly identify high-quality therapeutic candidates suitable for further scientific investigation and potential clinical development. Under the agreement, MedUni Vienna will receive the rights to utilize the technology for antibody generation and to further develop resulting antibodies for research, diagnostic, and therapeutic applications, while Nona Biosciences retains ownership of the Harbour Mice® platform and all associated intellectual property. The collaboration is expected to significantly enhance antibody discovery capabilities against clinically important viral targets while supporting future innovation in infectious disease research.
Collaboration Targets Infectious Diseases and Pandemic Preparedness
The partnership is designed to strengthen research focused on viral pathogens, particularly the development and characterization of fully human antibodies targeting viral spike proteins. By combining Prof. Florian Krammer’s expertise in infectious diseases with Nona’s proprietary antibody discovery technology, the collaboration aims to accelerate the identification of novel antiviral therapeutic candidates capable of addressing current and future infectious disease threats. Access to the H2L2 Harbour Mice® platform provides researchers with an expanded scientific foundation for discovering antibodies that may contribute to new antiviral medicines while supporting broader global efforts in pandemic preparedness. As emerging infectious diseases continue to pose significant public health challenges, rapid antibody generation platforms have become increasingly valuable for responding to future outbreaks with greater speed and precision.
Advertisement
Strategic Partnership Expands Biotherapeutic Innovation
The agreement further strengthens Nona Biosciences’ position in biotherapeutic discovery, demonstrating the versatility of its integrated technology platforms for advancing antibody-based drug development. Beyond the Harbour Mice® platform, the company continues to expand its innovation ecosystem through technologies supporting single-B cell screening, AI-driven drug discovery, CAR-T development, bispecific antibodies, antibody-drug conjugates (ADCs), and mRNA-based therapeutics. For MedUni Vienna, one of Europe’s leading biomedical research institutions, the collaboration enhances its ability to generate and evaluate fully human antibodies for future diagnostic and therapeutic applications. Together, the organizations aim to translate cutting-edge biotechnology into practical healthcare solutions that advance infectious disease research, improve preparedness for future pandemics, and accelerate the development of innovative antibody-based therapies capable of addressing critical global health needs.
Source: Nona Biosciences, Medical University of Vienna Fund Press release
